Form 4: Lexicon Pharmaceuticals Director Diane E. Sullivan Reports Stock Transactions

Director Diane E. Sullivan reports acquisition and disposal of Lexicon Pharmaceuticals common stock and restricted stock units on May 13, 2025.

Summary

• On May 13, 2025, Diane E. Sullivan, a director of Lexicon Pharmaceuticals, reported transactions involving the company's stock.
• Sullivan acquired 36,810 shares of common stock at a price of $0.
• Simultaneously, Sullivan disposed of 36,810 restricted stock units.
• Following these transactions, Sullivan directly owns 36,810 shares of Lexicon Pharmaceuticals common stock.
• The restricted stock units vest 100% on the first anniversary of the grant date and each unit represents one share of common stock.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions by a company director, with no inherent positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It allows investors to monitor the actions of company directors and officers, which can sometimes provide insights into their perspectives on the company's prospects.

Stakeholder Impact

• The transaction may be of interest to shareholders as it provides insight into the actions of a company director.

Key Dates

Keywords

Lexicon Pharmaceuticals, LXRX, Form 4, insider trading, stock transaction, Diane E. Sullivan, restricted stock units, common stock, director